Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Deutivacaftor→

Deutivacaftor Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1413431-07-8
Molecular formula
C24H19D9N2O3
Molecular weight
401.5 g/mol
Drug class
CFTR potentiatordeuterated ivacaftor component of vanzacaftor/deutivacaftor/tezacaftor combination
Mechanism of action
Enhances the open probability of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels at the cell surface. Deuteration modifies metabolic stability; its clinical use is as part of a fixed triple combination, not as a standalone API.
Indications / reported uses
  • Component of the fixed combination ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for treatment of cystic fibrosis in eligible patients aged 6 years and older who have at least one responsive CFTR mutation, under the current product label

Sources: US DailyMed — ALYFTREK prescribing information · US FDA — ALYFTREK approval · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Deutivacaftor Environmental Risk Assessment (ERA) (the Deutivacaftor ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.